

Ref. No.: WOCK/SEC/SE/2025-26/039

25th September, 2025

BSE Limited Corporate Relations Department P J Towers Dalal Street Mumbai - 400 001 <u>Scrip Code: 532300</u>	National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex Bandra (E) Mumbai - 400 051 <u>NSE Symbol: WOCKPHARMA</u>
--	---

Dear Sir/ Madam,

Subject: Submission pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") - Press Release

Pursuant to Regulation 30 of Listing Regulations, please find enclosed Press Release – “Prestigious Medical and Public Health Journal “THE LANCET Regional Health” Publishes Pivotal Phase 3 Clinical Study on Miqnaf® (Nafithromycin) – A Landmark for India’s Antibiotic Innovation”.

A copy of the same will also be uploaded on the Company’s website www.wockhardt.com.

Kindly take the same on record please.

Thanking you,
For **Wockhardt Limited**

Rashmi Mamtura
Company Secretary

Encls: A/a

Mumbai, 25th September 2025

Prestigious Medical and Public Health Journal “THE LANCET Regional Health” Publishes Pivotal Phase 3 Clinical Study on Miqna[®] (Nafithromycin) – A Landmark for India’s Antibiotic Innovation

THE LANCET Regional Health Southeast Asia, a globally respected and peer-reviewed journal has published the full results of the pivotal Phase 3 clinical study of Miqna[®] (nafithromycin) for the treatment of community-acquired bacterial pneumonia (CABP). This marks the first-ever publication in a LANCET journal for a novel drug discovered and developed in India, underlining the global relevance and scientific rigor of this study.

Miqna[®] is the first new macrolide antibiotic in over three decades, discovered, developed and launched in India, designed to address the growing challenge of multi-drug resistant CABP. It offers a convenient once-daily, three-day oral treatment regimen, a significant step toward improving compliance, minimizing hospitalization, and enhancing patient outcomes.

Robust Phase 3 Evidence

This first-of-its-kind Phase 3 study compared Miqna[®] directly with moxifloxacin, a gold-standard CABP drug in terms of efficacy. Conducted in nearly 500 patients, the trial demonstrated Miqna[®]'s non-inferior efficacy, with clinical improvement observed in >90% of patients as little as 3-4 days from treatment initiation. These results provide compelling evidence for Miqna[®] as a valuable alternative in the treatment of CABP, including infections caused by macrolide-resistant pathogens. In India, resistance to macrolides such as azithromycin and clarithromycin has reached alarming levels, approaching nearly 75%, according to the 2023 report by the Indian Council of Medical Research (ICMR).

Global Recognition and Clinical Impact

The *Lancet Regional Health* publication delivers a scientifically robust resource for clinicians worldwide, highlighting Miqna[®]'s potential to:

- Reduce CABP-related hospitalization burden
- Address antimicrobial resistance (AMR) through a dual mechanism of action
- Enable shorter, more effective treatment courses

With its convenient dosing and proven clinical outcomes, Miqna[®] represents an important advancement in the global fight against AMR.

A Milestone for Indian Drug Discovery

Miqna[®] is the third novel antibiotic successfully developed and launched from Wockhardt's antibiotic discovery program, reinforcing India's growing contribution to global antimicrobial innovation.

PRESS RELEASE

Saving Lives
55
years

WOCKHARDT

LIFE WINS

Wockhardt Limited

Registered Office:
D-4, MIDC, Chikalhana
Chhatrapati Sambhajinagar
431006, India
Tel.: +91-22-2653 4444
CIN: L24230MH1999PLC120720
www.wockhardt.com

The full publication could be accessed through [https://www.thelancet.com/journals/lansea/article/piiS27723682\(25\)001374/fulltext](https://www.thelancet.com/journals/lansea/article/piiS27723682(25)001374/fulltext)

About Miquaf®

Miquaf® is a novel, proprietary antibiotic developed by Wockhardt, for which several Phase 1 and a Phase 2 study were undertaken globally. The drug has gained Qualified Infectious Disease Product designation by US FDA.

About Wockhardt's Drug Discovery portfolio

For over 27 years, Wockhardt has been at the forefront of antibiotic innovation, focusing its drug discovery efforts on combating multi-drug resistant infections. This commitment has resulted in a strong pipeline of six antibiotics at various stages of clinical development and commercialization—all of which have been granted

Qualified Infectious Disease Product (QIDP) designation by the U.S. FDA. Three of these novel antibiotics are already approved for clinical use, while two more are in the final stages of development.



Wockhardt is employing around ~2900 people and 27 nationalities with presence in UK, Ireland, Switzerland, France, Mexico, Russia and many other countries. It has manufacturing and research facilities in India and UK and a manufacturing facility in Ireland. Wockhardt has a significant presence in Europe and India, with ~77% of its global revenues coming from international businesses.